July 6, 2005 -- Human Genome Sciences may finally have found something with market potential. The company that set the stage for the genomics revolution of the 90s always wanted to get into the clinic, though it proved to be harder to get there than anyone anticipated. Earlier, HGS reported good results in non-Hodgkin’s lymphoma (NHL) and still to come are results in colorectal cancer. Today, the Phase II data in non-small cell lung cancer (NSCLC) were announced. We look at the implications of the new drug - for patients and the company...
